Subscribe To
ALNY / Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran
![Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran](https://cdn.snapi.dev/images/v1/x/g/image-1421965187-2103382.jpg)
ALNY News
![Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues](https://cdn.snapi.dev/images/v1/h/i/284-2139645.jpg)
By Zacks Investment Research
November 3, 2023
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration more_horizontal
![Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran](https://cdn.snapi.dev/images/v1/x/g/image-1421965187-2103382.jpg)
By Seeking Alpha
October 13, 2023
Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran
We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is more_horizontal
![Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One](https://cdn.snapi.dev/images/v1/u/2/image-1141643124-2097916.jpg)
By Seeking Alpha
October 10, 2023
Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One
Despite a positive panel recommendation, the FDA rejected the Alnylam Pharmaceuticals, Inc. application to market Onpattro for ATTR-CM, citing a lack more_horizontal
![Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro](https://cdn.snapi.dev/images/v1/o/b/3739-2097286.jpg)
By Zacks Investment Research
October 10, 2023
Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro
Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL more_horizontal
![Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma](https://cdn.snapi.dev/images/v1/0/m/top-stocks-october-9-2023-tesla-bristol-myers-mirati-alnylam-pharma-2095834.jpg)
By Yahoo Finance
October 9, 2023
Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma
Tesla (TSLA) shares are in focus as China-made EV demand drops by 10%, affecting Model 3 and Y sales. Tesla's delivery and production data declined fr more_horizontal
![Alnylam Stock Is Dropping on Surprising FDA Rejection Alnylam Stock Is Dropping on Surprising FDA Rejection](https://cdn.snapi.dev/images/v1/h/8/biotech9-2095174.jpg)
By Barrons
October 9, 2023
Alnylam Stock Is Dropping on Surprising FDA Rejection
Drugmaker Alnylam wanted to expand approval of its drug Onpattro, but the Food and Drug Administration rejected the application even after an outside more_horizontal
![US FDA declines approval for expanded use of Alnylam's heart-disease drug US FDA declines approval for expanded use of Alnylam's heart-disease drug](https://cdn.snapi.dev/images/v1/a/o/ot6rc4sqxflrzgeqq5g7hkh4x4-2094790.jpg)
By Reuters
October 9, 2023
US FDA declines approval for expanded use of Alnylam's heart-disease drug
The U.S. Food and Drug Administration has declined to approve the expanded use of Alnylam Pharmaceuticals' drug to treat a rare and fatal heart diseas more_horizontal
![Alnylam to scrap sNDA for patisiran after receiving FDA complete response letter Alnylam to scrap sNDA for patisiran after receiving FDA complete response letter](https://cdn.snapi.dev/images/v1/4/5/biotech6-2094783.jpg)
By Market Watch
October 9, 2023
Alnylam to scrap sNDA for patisiran after receiving FDA complete response letter
Alnylam Pharmaceuticals Inc. ALNY, -1.00% said Monday it would no longer pursue its supplemental new drug application (sNDA) for patisiran as a treatm more_horizontal